Group 1 - The sixth batch of national organized high-value medical consumables centralized procurement has been conducted, resulting in selected products from 202 companies out of 227 that submitted bids, covering 12 types of medical consumables [1] - Drug-coated balloons, which improve vascular stenosis by expanding blood vessels and releasing medication, have been included in the procurement, with all 42 products from 32 companies selected, ensuring high clinical compatibility while reducing patient costs [1] - Urological intervention consumables, previously a "blank area" in procurement, saw 398 products from 170 companies selected, addressing the needs for various surgical procedures related to kidney and ureteral stones [1] Group 2 - Since 2020, the healthcare insurance department has conducted six batches of centralized procurement, successfully acquiring 142 types of medical consumables across nine major clinical fields, including cardiology, orthopedics, and urology [2] - The results of the procurement will be officially announced soon, with implementation expected around May 2026, allowing patients access to high-quality and affordable selected products [2]

2026.01. 14 本文字数：1424，阅读时长大约2分钟 作者 | 第一财经 郭晋晖 封图 | 第六批耗材集采按规则二、规则三"复活"的报价环节。/郭晋晖摄 1月13日，第六批国家组织高值医用耗材集中带量采购（下称"集采"）在天津开标，下午18时20分， 经过两轮现场报价，用时11个小时的第六批国家组织高值医用耗材集采报价环节全部结束。 1月14日上午，国家组织高值医用耗材联合采购办公室发布拟中选结果，本次集采纳入药物涂层球 囊、泌尿介入两大类12种医用耗材，共有227家企业的496个产品投标，202家企业的440个产品中 选。医疗机构需求量大的主流企业积极中选，产品供应丰富多元。 多位临床医生对记者表示，这些集采品种落地之后将惠及相关手术患者。 药物涂层球囊又进一步细分为冠状动脉药物涂层球囊及外周血管药物涂层球囊，冠状动脉药物涂层球 囊是继心血管冠脉支架之后心血管领域的第二次集采。 企业代表投标/郭晋晖摄 公证员现场开启投标箱/郭晋晖摄 泌尿外科高值耗材是首次进入集采，泌尿介入类则具体细分到输尿管介入导丝、输尿管介入鞘、输尿 管球囊扩张导管、泌尿取石网篮、一次性输尿管软镜导管、肾造瘘套件六类耗材。 第 ...

Core Insights - The sixth batch of centralized procurement for high-value medical consumables was held in Tianjin, resulting in the selection of 440 products from 202 companies out of 496 bids from 227 companies, indicating a diverse supply of products to meet clinical needs [1][2] Group 1: Procurement Details - The procurement includes 12 types of medical consumables, specifically drug-coated balloons and urological intervention materials, which are crucial for treating vascular and urinary conditions [1] - All 42 products from 32 companies in the drug-coated balloon category were selected, ensuring a high match with clinical usage while reducing patient costs [1] - In the urological intervention category, 398 products from 170 companies were selected, addressing a previously unaddressed area in centralized procurement [1] Group 2: Policy Implementation - The procurement aligns with the central government's policy to optimize procurement processes, emphasizing stability in clinical use, quality assurance, and prevention of price undercutting [2] - Group competition was implemented to ensure continuity in clinical usage, with products selected based on demand and supply capabilities [2] - The selection rules were optimized to prevent price undercutting, with a benchmark set at 65% of the average price when the lowest bid is excessively low, impacting 8 out of 20 competitive groups [2] Group 3: Historical Context - Since 2020, the healthcare insurance department has conducted six batches of centralized procurement, successfully acquiring 142 types of medical consumables across various clinical fields, including cardiology, orthopedics, and urology [2]

Core Insights - The sixth batch of high-value medical consumables procurement results has been announced, including 12 types of medical consumables in two categories: drug-coated balloons and urological interventions [1] - A total of 202 companies and 440 products have successfully been procured, with mainstream companies selected that have high demand from medical institutions, ensuring a diverse supply of products [1] - To date, the national medical insurance department has successfully procured 9 categories of 142 types of medical consumables, covering various clinical fields such as cardiology, orthopedics, peripheral vascular surgery, ophthalmology, otolaryngology, and urology [1] - Patients are expected to have access to the selected products from this procurement by around May 2026 [1]

Macro Economy - The Ministry of Industry and Information Technology (MIIT) issued an action plan for the high-quality development of industrial internet platforms from 2026 to 2028, aiming to have over 450 influential platforms and more than 120 million industrial devices connected by 2028, with a platform penetration rate exceeding 55% [2] - MIIT held the 18th manufacturing enterprise symposium, emphasizing active participation in industry rule-making and self-regulation to promote a win-win environment and protect industry development [2] Investment News - On January 13, A-shares experienced a collective pullback, with the Shanghai Composite Index ending a 17-day winning streak, closing down 0.64%. The total trading volume in Shanghai, Shenzhen, and Beijing reached 3.7 trillion, setting a new historical record [5] - The Hang Seng Index rose by 0.9%, with the Hang Seng Technology Index increasing by 0.11%. Pharmaceutical stocks performed well, with WuXi AppTec rising over 8% and WuXi Biologics nearly 6%. The H-share listing of Zhaoyi Innovation saw a peak increase of over 53% on its first day, closing with a 37.53% rise, valuing the company at 155.2 billion HKD [5] - As of January 12, the management scale of ETF products under Huaxia Fund officially surpassed 1 trillion RMB, reaching 1,016.424 billion RMB, making it the first domestic ETF manager to enter the "trillion club" [5] - Approximately 130 A-share listed companies have disclosed their 2025 performance forecasts, with around 70 companies expecting positive results, including profit increases and recoveries [5] - A total of 186 listed companies have been subject to concentrated research by public funds and brokerages, with the number of research instances reaching 220, indicating strong interest in popular stocks like Aipeng Medical and Entropy Technology [5] Company Movements - Guizhou Moutai is establishing a dynamic adjustment mechanism for retail prices based on market orientation, aiming for a "market-following, relatively stable" self-operated system [6] - The "Dead or Alive APP" will officially adopt the global brand name Demumu in its upcoming new version [7] - Alibaba Cloud has completed further strategic investment in ZStack, achieving a controlling stake, and plans to create a standardized and inclusive cloud-edge integrated solution [7] - DeepSeek published a new paper on conditional memory for large language models, co-authored with Peking University [7] - Huaxia Happiness expects a net loss of 16 billion to 24 billion RMB in 2025, with potential delisting risk warnings for its stock [8] - Zhongwen Online anticipates a net loss of 580 million to 700 million RMB in 2025, as its overseas short drama business is still in the investment phase [8] - Luxshare Precision has terminated its acquisition of the business asset package held by India's Wingtech [8]

Investment Rating - The industry maintains a "Neutral" rating, and the specific company, 恒瑞医药 (Hengrui Medicine), is rated as "Buy" [53] Core Insights - The sixth batch of centralized procurement for high-value medical consumables has been officially launched, covering drug-coated balloon products and urological intervention consumables [7][8] - The first domestically produced anti-CTLA-4 monoclonal antibody, 达伯欣® (Dabaoxin), has received approval from the National Medical Products Administration (NMPA) for marketing [8] - A weight-loss version of 司美格鲁肽 (Semaglutide) has gained approval for cardiovascular indications in China [9] - The SW pharmaceutical industry index has shown a 1.43% increase, with most sub-sectors experiencing growth [41] - The industry’s price-to-earnings ratio (TTM) is reported at 50.75 times, with a valuation premium of 259% relative to the Shanghai and Shenzhen 300 index [47] Industry News - The National Medical Insurance Administration has released a new drug catalog, which is expected to enhance the market potential for related pharmaceutical companies [52] - The recent approval of various drugs and clinical trials indicates a robust pipeline for innovative treatments in the industry [25][27][29][30][31][32][35] Company Announcements - Several companies, including 丽珠集团 (Lizhu Group) and 艾力斯 (Eli Lilly), have received approvals for new drug applications and clinical trials, indicating ongoing innovation and development in the sector [25][26][27][29][30] - 恒瑞医药 has been included in the list of breakthrough therapy products, highlighting its significant advancements in drug development [27] Market Review - The overall market has shown positive trends, with the Shanghai Composite Index rising by 2.15% and the Shenzhen Component Index increasing by 3.66% during the week [41] - The pharmaceutical sector's performance reflects a general upward trend, with specific sub-sectors like chemical pharmaceuticals and medical services leading the gains [41] Weekly Strategy - The report suggests focusing on pharmaceutical companies that have products entering the medical insurance catalog, as this could lead to increased market volume and investment opportunities [52]

Market Overview - On December 23, 2025, the A-share market saw all three major indices close higher, with the Shanghai Composite Index at 3919.98 points, up 0.07%, the Shenzhen Component Index at 13368.99 points, up 0.27%, and the ChiNext Index at 3205.01 points, up 0.41%. However, the overall market had more decliners than gainers, with over 3800 stocks declining. The total trading volume in the Shanghai and Shenzhen markets was 1.90 trillion yuan, an increase of 37.9 billion yuan from the previous trading day [1] - In the Hong Kong market, all three major indices turned negative, with the Hang Seng Index down 0.11% or 27.63 points, closing at 25774.14 points, and a total trading volume of 157.13 billion HKD. The Hang Seng China Enterprises Index fell 0.29% to 8913.83 points, while the Hang Seng Tech Index decreased by 0.69% to 5488.89 points [1] - In the U.S. market, the three major indices had mixed results, with the Dow Jones Industrial Average up 0.61% to 47716.42 points, the S&P 500 up 0.54% to 6849.09 points, and the Nasdaq Composite up 0.65% to 23365.69 points [1] New Stock Listing - The new stock "Jianxin Superconductor" listed on the Sci-Tech Innovation Board with a stock code of 688805, priced at 18.58 yuan per share and a price-to-earnings ratio of 61.97 times. The company is a leading player in the core components of medical magnetic resonance imaging (MRI) equipment, focusing on the R&D, production, and sales of superconducting magnets, permanent magnets, and gradient coils. It has established a comprehensive product matrix in the superconducting field, becoming the world's top independent supplier of superconducting magnets in the MRI industry [2] Important News - The Guangxi Futures Exchange announced adjustments to the trading fee standards, price fluctuation limits, and margin standards for platinum, palladium, and lithium carbonate futures contracts, effective from December 25, 2025. The trading fee for platinum and palladium futures will be adjusted to 0.025% of the transaction amount, while the fee for lithium carbonate futures will be set at 0.032%. The price fluctuation limit for platinum and palladium futures will be adjusted to 10%, with a margin requirement of 12% [3] - The sixth batch of national high-value medical consumables procurement has officially started, focusing on drug-coated balloons and urological intervention consumables, with bids opening on January 13, 2026. This round of procurement introduces two new features: the concept of anchor pricing and a multi-revival mechanism. The anchor pricing aims to balance price reduction and prevent malicious underpricing, helping to avoid excessive competition and collusion among companies [4]

Group 1 - The Ministry of Commerce of China strongly opposes the U.S. decision to include all foreign-produced drone systems and key components in the "untrusted supplier list," citing market distortion and unilateral bullying practices [1] - The sixth batch of national high-value medical consumables procurement has been officially launched, introducing new mechanisms such as anchor pricing and multiple reactivation mechanisms to prevent malicious low pricing [2] - Shanghai Gold Exchange has issued a notice to strengthen market risk control due to recent volatility in precious metal prices, urging members to enhance risk awareness and maintain market stability [3] Group 2 - Beijing has issued the first batch of L3-level highway autonomous vehicle special license plates, marking a significant milestone in the production of autonomous vehicles in China [4] - LME copper prices have reached a historical high of $12,001.99 per ton, indicating a strong upward trend in upstream resources, including gold and silver [5] - Semiconductor company SMIC has implemented a price increase of approximately 10% on certain production capacities, driven by rising demand from mobile applications and AI [6] Group 3 - U.S. third-quarter GDP growth exceeded expectations, leading to a collective rise in major U.S. stock indices, with the Dow Jones up 79.73 points and the Nasdaq up 133.02 points [7] - The U.S. dollar index fell by 0.34%, while gold and silver prices saw significant increases, with silver reaching a historical high of $71.5784 [9] - Despite the overall rise in indices, approximately 3,600 individual stocks declined, indicating a lack of coordination among stocks [10] Group 4 - A radioactive water leak incident occurred at a nuclear reactor in Japan, with approximately 20 milliliters of water leaking, but no significant radiation exposure to workers has been reported [11] - New regulations will be implemented in China starting January 1, 2026, prohibiting kindergartens from charging fees beyond tuition and care fees under various names [12] - Companies such as Guolian Aquatic Products and Dahu Co. are highlighted as potential investment targets in light of upcoming regulatory changes [12]

Group 1: Bond and Stock Market Trends - The bond ETF market has seen significant growth this year, with a total scale of 731.29 billion yuan, an increase of 557.26 billion yuan or 320.20% from the beginning of the year [1] - There has been a net inflow of 455.91 billion yuan into bond ETFs this year, a 455.33% increase compared to last year's net inflow of 82.10 billion yuan [1] - The number of newly established stock funds has surpassed 400 billion shares this year, marking a record high since 2022, with stock funds becoming a key focus for fund companies [1] Group 2: Interest Rates and Lending - In Shenzhen, the minimum interest rate for business loans secured by property has risen to 2.35% annually, up from a previous low of 2.20% [1] Group 3: Gold Prices - The international gold price has continued to rise, with the price of gold jewelry in RMB surpassing 1400 yuan per gram for the first time [2] Group 4: Panel Prices - According to TrendForce, TV panel prices are expected to stabilize in December, while laptop panel prices may face downward pressure due to supply chain issues [2] Group 5: Solar Industry Developments - The National Energy Administration aims for China's solar thermal power generation capacity to reach 15 million kilowatts by 2030, with the cost of electricity per kilowatt-hour expected to be comparable to coal power [3] Group 6: Medical Supplies Procurement - The sixth batch of national procurement for high-value medical consumables has been initiated, introducing new mechanisms to prevent malicious low pricing [4] Group 7: AI Market Developments - A report indicates that the top four AI applications by active users are Doubao, DeepSeek, Yuanbao, and Antifufu, with Doubao leading at 155 million weekly active users [5] Group 8: Corporate Governance Changes - Donghua Technology announced the resignation of its financial director, Gu Jianan, due to a transfer to another company [7] - Xinhua Net reported the resignation of its president, Shen Jiangying, due to work relocation [8] Group 9: Major Contracts and Projects - China Power Construction signed a contract worth approximately 6.626 billion yuan for a natural gas booster station project in Turkey [10] - Baosheng Co. won a contract worth about 1.2 billion yuan for a power cable project in Singapore, marking the largest overseas order in the company's history [11] Group 10: Stock Market Overview - The Shanghai Composite Index closed up 0.07%, with nearly 3900 stocks declining, while sectors like lithium batteries and Hainan Free Trade Zone showed strong performance [18]

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [1] Core Insights - The sixth batch of high-value medical consumables national centralized procurement has officially started, covering drug-coated balloon and urological intervention consumables, with a market scale exceeding 10 billion [4][9] - The procurement period is set until December 31, 2028, which will have a profound impact on the related industry chain and medical system [9] - Leading domestic companies are expected to gain more market share through successful procurement bids, despite short-term price declines impacting profit margins [6][14] Summary by Relevant Sections Industry Overview - The closing index is at 8269.04, with a 52-week high of 9323.49 and a low of 6764.34 [1] Recent Developments - The procurement document for drug-coated balloon and urological intervention consumables was released, marking the official start of the sixth batch of centralized procurement [4][9] - The procurement will include various high-value consumables, with specific annual demand quantities outlined for each type [10] Event Analysis - The procurement targets include drug-coated balloons for coronary arteries and peripheral blood vessels, as well as various urological intervention devices, with significant annual demand figures provided [10] - The highest effective bid prices will be determined based on provincial procurement prices and other pricing sources [11] Market Implications - The centralized procurement is expected to standardize the procurement and usage of medical consumables, improving industry ecology [14] - Companies with strong production cost reduction capabilities and good demand volumes are recommended for attention [6][14]